New hope for Tough-to-Treat ovarian cancer
NCT ID NCT05756907
Summary
This study tested whether combining two immunotherapy drugs (SON-1010 and atezolizumab) could help control advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The trial involved 40 patients with advanced solid tumors, including those with platinum-resistant ovarian cancer. Researchers aimed to find the safest dose and see if this combination could slow cancer growth better than current treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ashford Cancer Centre Research
Kurralta Park, South Australia, 5037, Australia
-
Blacktown Mt Druitt Hospital
Blacktown, New South Wales, 2148, Australia
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Sarcoma Oncology Center
Santa Monica, California, 90403, United States
-
The Border Cancer Hospital
Albury, New South Wales, 2640, Australia
-
University of Southern California
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.